The Market Overreacted to the DEA's Marijuana Rescheduling -- Here's What It Means for Canopy Growth Stock Now

The DEA's rescheduling of marijuana from Schedule I to Schedule III in April 2026 was initially seen as historic but has had muted impact. The rescheduling only applies to medical marijuana and provides limited benefits like IRS Section 280E relief. Canopy Growth, a major Canadian cannabis company, cannot fully capitalize on these changes due to its non-controlling interest in its U.S. affiliate Canopy USA, whose results remain unconsolidated. The analyst concludes the rescheduling won't materially affect Canopy Growth soon and does not recommend the stock as a buy.

06/02/2026, 1:15 AM • The Motley Fool

Canopy Growth Is Restating Two Years of Financials Before June 15 Earnings -- Here's What CGC Investors Need to Know Right Now

Canopy Growth announced it will restate financial results for two years due to a technical accounting error involving share-settled warrants that should have been classified as liabilities rather than equity. The company states the restatement won't impact revenue, operating income, cash flows, or key performance metrics. However, the stock remains a risky penny stock in a struggling marijuana sector facing intense competition and illicit market pressures. Most investors should avoid the stock until it achieves sustainable profitability and the restatement is complete.

05/22/2026, 11:15 PM • The Motley Fool

Is Canopy Growth Stock Finally Setting Up for a Real Turnaround?

Canopy Growth has reduced debt and accumulated cash, but achieved this through significant share dilution. The company remains unprofitable even on an EBITDA basis. However, the recent acquisition of MTL Cannabis could create cost synergies and improve profitability. Investors are advised to wait for the May 29 earnings release before making investment decisions.

05/15/2026, 12:30 PM • The Motley Fool

Canopy Growth Is One of the Market's Most Polarizing Stocks: 3 Scenarios for the Next 12 Months

Canopy Growth shows early signs of stabilization after years of losses and restructuring, with narrowing EBITDA losses and 8% revenue growth in Canadian adult-use cannabis. However, investors remain divided on whether this represents a genuine turnaround or merely an extension of decline, given persistent industry oversupply, pricing pressure, and the company's continued unprofitability.

05/14/2026, 6:15 AM • The Motley Fool

New Cannabis Rules Just Created Winners and Losers: What the Split Schedule Means for Medical Operators and MSOs

New federal cannabis tax rules are reshaping the industry with a split schedule that benefits medical-only operators while challenging multi-state operators. Medical-only companies like Trulieve could see faster margin and cash-flow improvements, while multi-state cannabis companies may face new tax-allocation hurdles that pressure near-term earnings.

04/30/2026, 4:20 PM • The Motley Fool

Canopy Growth Is Rallying Again. But Is It a Dead Cat Bounce?

Canopy Growth shares have surged 25% over the past month, but the article warns this may be a dead cat bounce. Despite recent positive moves like debt reduction and a medical marijuana acquisition, the company remains unprofitable since 2017 and faces significant headwinds from competition, regulation, and illicit market competition. The stock's penny status means large percentage gains can represent minimal dollar movements, and most investors should avoid it until profitability is proven.

04/24/2026, 6:15 PM • The Motley Fool

From $500 to $1: Is Canopy Growth a Dead Stock Walking or the Ultimate Turnaround Play?

Canopy Growth has lost 99.6% of its value over five years due to persistent profitability challenges, inability to enter the U.S. market directly, heavy cash burn, and shareholder dilution. While the stock could experience a dead cat bounce, long-standing issues and political gridlock limiting federal marijuana legalization make further downside possible. The article recommends financially stronger cannabis alternatives like Green Thumb Industries and Cronos Group, or marijuana ETFs, as better investment choices.

04/22/2026, 6:10 AM • The Motley Fool

Is It Time to Dump Your Shares of Canopy Growth?

Canopy Growth, a Canadian marijuana leader, has plummeted 99% from its all-time high of $568 to around $1 per share. The company faces intense competition, has yet to achieve sustainable profitability, and is undertaking an acquisition that will dilute shareholders while weakening its balance sheet. Investors with significant losses may consider selling to harvest tax losses, as a return to previous highs seems unlikely in the near term.

03/07/2026, 5:15 AM • The Motley Fool

Is Canopy Growth Stock Going to $0?

Canopy Growth's stock has plummeted from over $300 to under $2 per share. Despite modest improvements in net loss per share, the company continues to post weak financial results with flat revenue and declining free cash flow. While recent cannabis reclassification in the U.S. offers some regulatory progress, the analyst argues the company faces insurmountable challenges including stiff competition, inability to transport cannabis across state lines, and failure to succeed even in the legalized Canadian market. The analyst concludes the stock is likely headed to $0 and recommends avoiding the investment.

03/03/2026, 4:30 PM • The Motley Fool

Is It Time to Dump Your Shares of Canopy Growth?​

Canopy Growth stock has collapsed from a peak of $568 per share to around $1.15, making it a money-losing penny stock with shareholder dilution concerns. The article suggests investors who bought at highs consider selling to harvest tax losses rather than holding onto the investment hoping for a recovery, as the marijuana sector enthusiasm has significantly cooled.

02/26/2026, 9:30 AM • The Motley Fool

Canopy Growth or Tilray Brands: Which Stock Is More Likely to Be a Millionaire Maker?

The article compares two major cannabis stocks, Tilray Brands and Canopy Growth, as potential long-term investments following recent U.S. regulatory developments. While both companies have improved financial results and positioned themselves to capitalize on emerging cannabis market opportunities, the author concludes that neither is likely to be a millionaire maker due to significant regulatory uncertainty and industry challenges. However, Tilray is recommended as the better choice due to its greater operational diversification and geographic presence.

02/20/2026, 11:30 AM • The Motley Fool

Recreational Cannabis Market Report 2026-2035: A $3.32 Billion Market by 2030 - AI-Enabled Product Innovation, Novel Cannabis Beverages and Experience-Based Offerings Reshape Premiumization

The recreational cannabis market is projected to grow from $2.24 billion in 2025 to $3.32 billion by 2030, with a CAGR of 7.8-8.2%. Growth is driven by increasing legalization, public acceptance, demand for high-THC products, and innovation in premium edibles, beverages, and vape formats. Key players are launching innovative products and pursuing strategic acquisitions to capitalize on expanding market opportunities.

02/20/2026, 5:59 AM • GlobeNewswire

MTL Cannabis Announces Shareholder Approval of Arrangement with Canopy Growth

MTL Cannabis Corp. shareholders have approved a special resolution authorizing Canopy Growth Corporation to acquire all issued and outstanding common shares of MTL Cannabis. The arrangement, agreed upon in December 2025, received 99.97% approval from all MTL shareholders and 99.80% from minority shareholders. MTL Cannabis expects to seek final court approval on February 23, 2026, with closing expected before the end of March 2026.

02/18/2026, 7:30 AM • Benzinga

MTL Cannabis Reminds MTL Shareholders to Vote FOR the Arrangement Resolution to Approve the Proposed Plan of Arrangement with Canopy Growth at the Upcoming Special Meeting of MTL Shareholders

MTL Cannabis Corp. urges shareholders to vote in favor of its proposed arrangement with Canopy Growth Corporation at a special meeting on February 17, 2026. Under the deal, MTL shareholders will receive 0.32 Canopy Growth shares plus $0.144 in cash per MTL share, representing an 82% premium to the December 12, 2025 closing price. The arrangement is expected to provide MTL shareholders with enhanced liquidity, exposure to Canopy Growth's global cannabis operations, and potential cost synergies of approximately $10 million annually. Both the MTL board and independent proxy advisors ISS and Glass Lewis recommend voting in favor.

02/10/2026, 8:30 AM • Benzinga

Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend MTL Shareholders Vote FOR the Arrangement Resolution with Canopy Growth

Leading proxy advisory firms ISS and Glass Lewis have recommended MTL Cannabis shareholders vote in favor of the proposed arrangement with Canopy Growth. Under the deal, Canopy Growth will acquire all MTL shares, with each shareholder receiving 0.32 Canopy shares plus $0.144 in cash per MTL share. Both firms cited the meaningful premium to the unaffected share price and the combination of immediate liquidity with ongoing upside participation as reasons for their recommendation. The MTL Board unanimously supports the arrangement, with the shareholder vote scheduled for February 17, 2026.

02/05/2026, 8:30 AM • Benzinga